This company is a specialty biopharmaceutical company that has established a drug development platform to actualize an orally administered, low-dose version of the drug interferon, which is a well characterized immune system modulator. Interferon serves as one of the most…
Urovalve announced promising early results this week in a multi-site clinical trial of its Surinate Bladder Management System.
The company’s lead product is Restanza (cethromycin), a novel once-a-day antibiotic for the treatment of life-threatening bacterial infections and bioterror pathogens.
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
While most people are familiar with the big-name heart problems such as cardiac arrest and congestive heart failure, PAD is often overlooked.
Approximately 250,000 new diagnoses of MR are made each year, but only about 50,000 patients undergo surgery to fix the problem.
A recent study commissioned by the Society of Actuaries and completed by Milliman, Inc., highlighted both the high personal and financial costs exacted by measurable medical errors.
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
Cardiogenesis, a medical device company that develops tools for the treatment of ischemic cardiac disease, has helped numerous heart-disease patients with the use of laser therapy.
The technology company has developed CaseReader, a turnkey software solution designed to help radiologists conduct faster, more accurate analyses.
Copyright © 2024 | WordPress Theme by MH Themes